Submit Ideas to Boost Clinical Research Awareness
INC Research and CISCRP will be accepting applications for its joint "Inspiring Hope" Ideathon beginning June 1. The ideathon is a crowd-solving event aimed at solving the problem of community awareness of clinical research. Idea applications will be accepted June 1 through August 8, and will be evaluated on innovation, feasibility, sustainability and impact. Finalists will collaborate live with a multifunctional team in a crowd-solving-type environment to further develop and ultimately present their solution to an expert judging panel at the Ideathon event Sept. 27-28 in Boston. The winner will be named at the conclusion of the event, with INC Research and CISCRP to work with the winning team to turn the idea into a viable solution.
Read the full release here
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
